Santiago Darlene, Mendoza Adlin, Morales Zuleyka, Santos Javier
School of Pharmacy, University of Puerto Rico;
School of Pharmacy, University of Puerto Rico.
J Pharm Innov. 2020 Sep;15(3):357-364. doi: 10.1007/s12247-019-09377-5. Epub 2019 Mar 13.
Hot melt extrusion (HME) has demonstrated to be an adequate compounding method for poorly-soluble pharmaceutical drugs, as it increases its solubility by fixing its amorphous solid-state using polymers (plasticizing) and other ingredients (non- plasticizing). However, it's amorphous state of the drug and the stability of the amorphous state will greatly depend on its interactions with these (plasticizing or not).
In this study, we aimed at characterizing the impact of the combination of plasticizing (TPGS) and anti-plasticizing (PVP) ingredients in amorphous celecoxib prepared using HME in terms of chemical interactions between the components (FTIR, Raman and NMR), viscoelasticity (loss and storage modulus) and required energy for flow (activation energy). Different celecoxib/PVP/TPGS ratios were studied to understand the synergistic effect of PVP and TPGS in inhibiting the crystallization of celecoxib when preparing amorphous dispersions using HME. We aimed at linking the viscoelastic properties of the melt with the resulting amorphous state described by the chemical interactions upon extrusion.
The amorphous state of celecoxib was evidenced by strengthening of H-bonding between celecoxib and PVP, lack of characteristic crystalline peaks of celecoxib, and deshielding of aromatic protons. The melt was also characterized in terms of viscoelastic temperature dependent behavior (liquid G"; elastic G'), where increasing amounts of TPGS and PVP showed opposites effects; TPGS reduced the viscoelastic response whereas PVP increased it. Calculated melt activation energies (Ea) from the temperature dependent viscosity revealed a threshold of TPGS concentration where samples with 1% w/w of TPGS showed higher flow activation energies (higher Ea) independent of the drug/polymer ratios, compared to samples with higher amounts of TPGS.
Low drug content combined with anti-plasticizing (PVP) amounts and relatively low plasticizing (TPGS) amounts yields an amorphous dispersion that is characterized with strong H-bonding due to efficient mixing using HME.
热熔挤出(HME)已被证明是一种适用于难溶性药物的混合方法,因为它通过使用聚合物(增塑)和其他成分(非增塑)固定药物的无定形固态来提高其溶解度。然而,药物的无定形态及其稳定性将极大地取决于它与这些成分(是否增塑)的相互作用。
在本研究中,我们旨在通过HME制备的无定形塞来昔布中,从各成分之间的化学相互作用(傅里叶变换红外光谱、拉曼光谱和核磁共振)、粘弹性(损耗模量和储能模量)以及流动所需能量(活化能)方面,表征增塑成分(聚乙二醇维生素E琥珀酸酯)和抗增塑成分(聚乙烯吡咯烷酮)组合的影响。研究了不同的塞来昔布/聚乙烯吡咯烷酮/聚乙二醇维生素E琥珀酸酯比例,以了解在使用HME制备无定形分散体时,聚乙烯吡咯烷酮和聚乙二醇维生素E琥珀酸酯在抑制塞来昔布结晶方面的协同作用。我们旨在将熔体的粘弹性性质与挤出时化学相互作用所描述的最终无定形态联系起来。
塞来昔布与聚乙烯吡咯烷酮之间氢键的增强、塞来昔布特征结晶峰的缺失以及芳环质子的去屏蔽证明了塞来昔布的无定形态。熔体还根据粘弹性随温度的变化行为(粘性G";弹性G')进行了表征,其中聚乙二醇维生素E琥珀酸酯和聚乙烯吡咯烷酮含量的增加表现出相反的效果;聚乙二醇维生素E琥珀酸酯降低了粘弹性响应,而聚乙烯吡咯烷酮则增加了粘弹性响应。根据温度依赖性粘度计算出的熔体活化能(Ea)显示,聚乙二醇维生素E琥珀酸酯浓度存在一个阈值,与聚乙二醇维生素E琥珀酸酯含量较高的样品相比,含1%w/w聚乙二醇维生素E琥珀酸酯的样品显示出更高的流动活化能(更高的Ea),且与药物/聚合物比例无关。
低药物含量与抗增塑剂(聚乙烯吡咯烷酮)用量以及相对较低的增塑剂(聚乙二醇维生素E琥珀酸酯)用量相结合,可得到一种无定形分散体,其特征是通过HME有效混合形成了强氢键。